Patents Assigned to Wyeth
  • 5-(Substituted)-5-(substitutedsulfonyl or sulfanyl) thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6716862
    Abstract: The invention relates to compounds of Formula (I) wherein R1, (R2)v, R3 and n are defined in the specification and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: April 6, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Edward James Salaski, Semiramis Ayral-Kaloustian, Joseph William Epstein
  • Process for synthesis of 2-yl chroman derivatives
    Patent number: 6716998
    Abstract: This invention provides a process for the stereospecific preparation of 2-yl-chroman and -chromene derivatives of the formula: These compounds are useful for the preparation of optically active 2-aminomethyl- and 2-azaheterocyclylmethyl-chromans.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: April 6, 2004
    Assignee: Wyeth
    Inventor: Jonathan L. Gross
  • Bazedoxifene treatment regimens
    Publication number: 20040063692
    Abstract: This invention relates to extended dosing regimens for the selective estrogen receptor modulator bazedoxefine (1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1 H-indol-5-ol).
    Type: Application
    Filed: June 13, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth
    Inventors: Barry Samuel Komm, Simon Nicholas Jenkins, James Charles Ermer, Mark Andrew Collins, Geraldine Marie Ferron, Pol Boudes, Wendy Ann Dulin
  • 8-AZA-bicyclo[3.2.1]octan-3-OL derivative of 2,3-dihydro-1,4-benzodioxan as 5-HT 1A antagonists
    Publication number: 20040063728
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: September 16, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth
    Inventors: Adam M. Gilbert, Gary P. Stack
  • 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Publication number: 20040063971
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Application
    Filed: September 26, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Publication number: 20040063777
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Application
    Filed: September 26, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction
    Publication number: 20040063721
    Abstract: The present invention relates to a method for treating thermoregulatory disorders by administering compounds and compositions of compounds which by modulating 5HT levels activate the 5HT2a receptor. The invention also relates to therapy using 5HT1a antagonists and SRIs in combination and pharmaceutical compositions and products containing it. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: August 14, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth
    Inventors: Darlene Coleman Deecher, Istvan Jozsef Merchenthaler, Liza Leventhal, Kimberly Jean Sipe, Lawrence Thomas O'Connor, Terrance Andree
  • Infant formula containing partially hydrolyzed isolated soy protein with a reduced phytate content
    Publication number: 20040062849
    Abstract: Nutritional formulas are provided which comprise isolated soy protein wherein the isolated soy protein has a phytate content of 100 mg per liter or less; and the isolated soy protein has a degree of hydrolysis between 5 and 20%.
    Type: Application
    Filed: September 16, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth
    Inventors: Eric L. Lien, Charles F. Kuhlman
  • Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors
    Publication number: 20040063904
    Abstract: The invention is a process for the preparation of compounds of the Formula I: 1
    Type: Application
    Filed: September 18, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Yanzhong Wu, Sreenivasulu Megati, Constantine Gletsos, John Thomas Kendall, Bogdan Kazimierz Wilk, Thurairajah Padmanathan, Panolil Raveendranath
  • Process for synthesizing N-aryl piperazines with chiral N?-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
    Patent number: 6713626
    Abstract: A process for formation of N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane side-chains having the structure shown in formula below, and for making intermediate compounds therefor. In this process, chirality is introduced at the piperazine ring formation step and 2-aminopyridyl substitution is incorporated via displacement. The resulting N,N′ disubstituted piperazines act on the central nervous system at 5HT receptors.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: March 30, 2004
    Assignee: Wyeth
    Inventors: Gregg Brian Feigelson, Joseph Zeldis, Ivo Jirkovsky
  • Pregnanes
    Patent number: 6713465
    Abstract: This invention provides a pharmaceutically acceptable salt of 5&agr;-pregn-16-en-3&bgr;-ol-20-one 3-sulfate ester, which is useful as a progestational agent.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: March 30, 2004
    Assignee: Wyeth
    Inventors: Reinhold H. W. Bender, Mahdi B. Fawzi, Horace Fletcher, III, George O. Morton, Syed M. Shah, Xuejun Tang
  • Substantially pure glycopeptide antibiotics AC-98-1; AC-98-2; AC-98-3; AC-98-4 and AC-98-5
    Patent number: 6713448
    Abstract: The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism Streptomyces hygroscopicus.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: March 30, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Guy Thomas Carter, Haiyin He
  • Cyclocarbamate derivatives as progesterone receptor modulators
    Patent number: 6713478
    Abstract: This invention provides compounds of Formula (I): wherein R1 and R2 are independent substituents or are fused to form spirocyclic rings; R3, RC, and R4 are as defined herein; and R5 is a substituted benzene ring or a substituted five or six membered heterocyclic ring having in its backbone 1, 2, or 3 heteroatoms including O, S, SO, SO2 or NR6; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: March 30, 2004
    Assignees: Wyeth, Ligand Pharmaceuticals, Inc.
    Inventors: Puwen Zhang, Eugene A. Terefenko, Andrew Fensome, Jay E. Wrobel, Horace Fletcher, III, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
  • Effector proteins of Rapamycin
    Patent number: 6713607
    Abstract: This invention comprises novel Rapamycin-FKBP12 binding proteins of mammalian origin for identification, design and synthesis of immunomodulatory, anti-restenosis or anti-tumor agents, as well as fragments of the proteins and the DNA, cDNA, antisense RNA and DNA segments corresponding to the proteins. This invention also comprises methods for isolating the proteins and therapeutic uses related to the proteins.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: March 30, 2004
    Assignee: Wyeth
    Inventors: Thomas J. Caggiano, Yanqiu Chen, Amedeo A. Failli, Katherine L. Molnar-Kimber, Koji Nakanishi
  • Pneumococcal vaccines formulated with interleukin-12
    Patent number: 6709658
    Abstract: This invention pertains to vaccine compositions comprising a mixture of antigen, such as a pneumococcal or meningococcal antigen, and interleukin IL-12, which may be adsorbed onto a mineral in suspension. The pneumococcal or meningococcal antigen may be conjugated to a carrier molecule. These vaccine compositions modulate the protective immune response to the antigen.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: March 23, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Vincent J. LaPosta, John H. Eldridge
  • 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6710069
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: March 23, 2004
    Assignee: Wyeth
    Inventors: Ping Zhou, Michael Gerard Kelly
  • 5-Substituted-3(2H)-furanones useful for inhibition of farnesyl-protein transferase
    Patent number: 6710078
    Abstract: Compounds of Formula (I): wherein R1, R2, R3, X, Y, Z and Q are as defined in the specification which compounds are inhibitors of Ras farnesyl-protein transferase enzyme (FPTase), and useful in treating ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid and processes for the preparation of said compounds of Formula (I).
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: March 23, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Semiramis Ayral-Kaloustian, Irwin Hollander, Ann Aulabaugh
  • Truncated aggrecanase molecules
    Publication number: 20040054149
    Abstract: Truncated aggrecanase proteins and nucleotides sequences encoding them as well as processes for producing them are disclosed. Additionally, aggrecanases with amino acid mutations that lead to increased stability and expression levels in comparison with wild-type or native aggrecanases are also disclosed. Aggrecanases of the invention are especially useful for development of compositions for treatment of diseases such as osteoarthritis. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.
    Type: Application
    Filed: February 5, 2003
    Publication date: March 18, 2004
    Applicant: Wyeth
    Inventors: Katy E. Georgiadis, Tara K. Crawford, Kathleen N. Tomkinson, Lisa A. Collins-Racie, Christopher J. Corcoran, Bethany A. Freeman, Edward R. Lavallie
  • Monoclonal antibody specific for an epitope of inactivated feline immunodeficiency-encoded glycoprotein
    Publication number: 20040053224
    Abstract: The present invention provides a monoclonal antibody specific for an epitope which is unique to the surface protein component of an inactivated feline immunodeficiency virus (FIV) envelope glycoprotein. Said antibody is useful for the quantification of inactivated FIV or the determination of the potency of an inactivated FIV vaccine.
    Type: Application
    Filed: August 26, 2003
    Publication date: March 18, 2004
    Applicant: Wyeth
    Inventor: Chengjin M. Huang
  • Process for preparing 6-alkylidene penem derivatives
    Publication number: 20040053913
    Abstract: The present invention provides a process of making compounds of formula I, which are useful for the treatment of bacterial infection or disease.
    Type: Application
    Filed: May 1, 2003
    Publication date: March 18, 2004
    Applicant: Wyeth
    Inventors: Takao Abe, Hiroshi Matsunaga, Ado Mihira, Chisato Sato, Hideki Ushirogochi, Koichi Sato, Tsuyoshi Takasaki, Aranapakam Mudumbai Venkatesan, Tarek Suhayl Mansour